© Drug Hunter Inc. 2018-2023
Home > AG-636
dihydroorotate dehydrogenase inhibitor
in Ph. I for RR-lymphoma
from opt. of literature molecule
Mol. Cancer Ther., Oct. 20, 2020
Agios Pharmaceuticals, Cambridge, MA
AG-636 (Agios Pharmaceuticals dihydroorotate dehydrogenase (DHODH) inhibitor clinical candidate)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year